MedTrace Logo

The Effect of Gemcabene on Insulin Sensitivity in Nondiabetic Subjects

NCT02586168 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2020-04-09

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of gemcabene on insulin sensitivity as defined by average glucose disposal rate.

Conditions

  • Insulin Sensitivity

Interventions

DRUG

Gemcabene 900 mg

Gemcabene 900 mg once daily (QD)

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • NeuroBo Pharmaceuticals Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-07-31
Primary Completion
2001-10-31
Completion
2001-10-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02586168 on ClinicalTrials.gov